Full 3rd Circ. Won’t Rethink $45M CareDx False Ad Case

By Editorial Team

The Third Circuit on Tuesday turned down medical testing company CareDx’s request to have a full panel mull whether to reinstate a $45 million jury award in a false advertisement case over genetic testing technology against rival Natera.

The decision by the Third Circuit means that the $45 million jury award in the false advertisement case against Natera will not be reconsidered. CareDx had sought a review by a full panel of judges to potentially reinstate the jury award.

The case involved allegations of false advertising related to genetic testing technology between CareDx and Natera. The jury had initially awarded CareDx $45 million in damages, but Natera appealed the decision.

Despite CareDx’s efforts to have the decision reconsidered, the Third Circuit’s ruling stands, marking a significant development in the ongoing legal battle between the two companies.

Law360 is closely following this case and providing updates on the latest developments. Stay tuned for more information as the story unfolds.